Stephen L. Huhn MD

Chief Medical Officer Dunad Therapeutics

1 BroadwayCambridge, MA 02142

Dr. Huhn is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Huhn's full profile Already have an account?

Education & Training

University of MarylandResidency, Neurological Surgery, 1988 - 1993
University of Maryland Medical Center Midtown CampusInternship, Transitional Year, 1987 - 1988
University of Arizona College of MedicineClass of 1987

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CA State Medical License 1993 - 2027
American Board of Neurological Surgery Neurological Surgery

Awards, Honors, & Recognition

Fellow American Academy of Pediatrics
Fellow (FACS) American College of Surgeons
Fellow (FAANS) American Association of Neurological Surgeons

Clinical Trials

Study of Human Central Nervous System (CNS) Stem Cells Transplantation in Pelizaeus-Merzbacher Disease (PMD) Subjects
COMPLETED
PHASE1
Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Patients With Thoracic Spinal Cord Injury
COMPLETED
PHASE1, PHASE2
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers Start of enrollment: 2018 Mar 30
COMPLETED
PHASE1

Publications & Presentations

PubMed

39 citations
Long-Term Safety, Immunologic Response, and Imaging Outcomes following Neural Stem Cell Transplantation for Pelizaeus-Merzbacher Disease.
Nalin Gupta, Roland G. Henry, Sang-Mo Kang, Jonathan B. Strober, Daniel A. Lim
Stem Cell Reports. 2019-08-13
Long-Term Safety, Immunologic Response, and Imaging Outcomes following Neural Stem Cell Transplantation for Pelizaeus-Merzbacher Disease.
Nalin Gupta, Roland G Henry, Sang-Mo Kang, Jonathan Strober, Daniel A Lim
Stem cell reports. 2019-08-06
12 citations
Subretinal Transplantation of Human Central Nervous System Stem Cells Stimulates Controlled Proliferation of Endogenous Retinal Pigment Epithelium.
Trevor J. McGill, Linda Osborne, Bin Lu, Jonathan Stoddard, Stephen L. Huhn
Translational Vision Science & Technology. 2019-05-01

Press Mentions

Pipeline Therapeutics Receives IND Clearance from FDA to Initiate Phase 1b/2a Study of PIPE-307 in Patients with Relapsing-Remitting Multiple SclerosisMarch 28th, 2022
Pipeline Therapeutics Reports Positive Phase 1 Clinical Results for PIPE-307, a Neuroregenerative Therapeutic for the Treatment of Multiple SclerosisMarch 10th, 2022
Pipeline Testing PIPE-307 Remyelinating Compound in Healthy VolunteersMarch 9th, 2021